Lonza, a global leader in biological manufacturing, and Forty Seven, Inc., a clinical-stage immuno-oncology company, announced today a strategic manufacturing agreement for the clinical supply of Forty Seven’s therapeutic antibodies. Under the agreement Lonza will manufacture material at its Slough (UK) facility for Forty Seven’s ongoing and future clinical trials. Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Its lead molecule, Hu5F9-G4, is a…